The Latest Cardiac and Vascular News
STRONG-HF study primary outcomes showed significant reduction of all cause death or acute heart failure readmissions, at day 180, when the study strategy was implemented Rapid, simultaneous up-titration of therapies, and close follow-up, led to increased patient quality of life. The Roche Elecsys® NT-proBNP biomarker is an integral part of the treatment […]
– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline, Planned Scientific Focus, and Future Growth Drivers – – Virtual Program Begins at 10am ET Today, Wednesday, November 9th – ANN ARBOR, Mich., Nov. […]
Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented a new analysis […]
Company named a Top 8 Super Finalist in the global health tech competition identifying the most disruptive companies shaping the future of digital health. CAMBRIDGE, Mass., Nov. 8, 2022 /PRNewswire/ — Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced it has been selected to participate in the Health […]
DUBLIN and CHICAGO, Nov. 7, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented today as Late-Breaking Clinical Science at the American Heart Association (AHA) Scientific Sessions 2022. With this news, Medtronic […]
LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced results from a preclinical study of […]
VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for […]
Salt Lake City, UT, Nov. 08, 2022 (GLOBE NEWSWIRE) — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without standard modifiable heart risk factors who experience a heart attack are common and more likely to fare better than heart-attack patients with known risk […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 11th Annual Meeting, “The CEO + CFO Roundtable.” The conference is taking place this week, November 7-10, 2022, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, Meesha Dogan, CEO, […]
– ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia – ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia – Olpasiran reduced lipoprotein(a) levels […]
